Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.46 |
| ▸ | PHGDH | O43175 | 6/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004113 | 0.84 | ACLY (0.60) | ACLYPHGDHRXRARXRBTSHR | |
| SCHEMBL3381195 | 0.81 | ACLY (0.51) | ACLYPHGDHRXRARXRBTSHR | |
| SCHEMBL31400972 | 0.81 | ACLY (0.51) | ACLYPHGDHRXRARXRBTSHR | |
| SCHEMBL9868370 | 0.77 | RARB (0.60) | RXRARXRB | |
| SCHEMBL5332167 | 0.76 | KMT2A (0.60) | ACLYKMT2AKDM4E | |
| SCHEMBL22004112 | 0.70 | ACLY (0.57) | ACLYPHGDHRXRARXRBTSHR | |
| SCHEMBL22004299 | 0.70 | ACLY (0.59) | ACLYPHGDH | |
| SCHEMBL22005118 | 0.70 | ACLY (0.55) | ACLYKMT2A | |
| SCHEMBL6707155 | 0.70 | MAPT (0.46) | ACLYKDM4ENPC1RAB9A | |
| SCHEMBL22004304 | 0.70 | ACLY (0.63) | ACLYPHGDHRXRARXRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205751-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1648885-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009993-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205751-A1 | Novel compounds | KCNN2, KCNN3, KCNN1 | ACLY 2364/4885PHGDH 2415/4885RPA1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.